Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811850 · ClinicalTrials.gov registry record · Phase 4
Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00811850: Completed Phase 4 study, sponsored by Allergan.
NCT00811850 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00811850, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.
Primary Outcome
Peak systolic velocity (PSV) of retrobulbar blood flow as measured by color Doppler imaging (CDI) in the nasal short posterior ciliary artery after 1 month of treatment. CDI is a high-resolution ultrasound system which provides visualization of the flow of blood through a vessel. PSV is the maximum blood flow speed within a vessel at the time of systole (maximum pressure exerted in a blood vessel).
Interventions
- DRUG fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
- DRUG fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
What the finished NCT00811850 record still lists
NCT00811850 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution is the first listed.
NCT00811850 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00811850 about?
NCT00811850 is a clinical study titled "Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow". A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) o...
What is the current status of trial NCT00811850?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2008-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00811850?
The interventions under investigation include: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (DRUG), fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00811850?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00811850's enrollment target sits among peer trials
15 1880th of 2000 higher than 100 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia